Image: Public domain | via Wikimedia Commons
Jordi Rubiralta, at the age of 52, is a prominent figure in the healthcare industry, deriving his wealth from Werfen, a diagnostics company based in Madrid. His career has been marked by his leadership as Chairman of Werfen until 2019 and his current role on the board. Rubiralta's achievements include driving the expansion of Werfen, with notable acquisitions such as Tem and Accriva Diagnostics. His contributions to the diagnostics sector have solidified his position as a billionaire.
Jordi Rubiralta's background is rooted in the diagnostics industry, stemming from the founding of Werfen by his father, Josep María Rubiralta, and his uncle Francisco in 1966.
Jordi Rubiralta played a crucial role in the growth and expansion of Werfen. He chaired the company until 2019 and remains on the board. He spearheaded the company's expansion in Germany and the U.S. through strategic acquisitions, including Tem and Accriva Diagnostics. He currently serves as the president of the family office Yukon Capital.
Under Rubiralta's leadership, Werfen has focused on the manufacturing of medical diagnostic instruments. The company's business lines include hemostasis, acute care diagnostics, transfusion, autoimmunity, and transplants. The company has a strong presence in the diagnostics market, employing nearly 7,000 people globally.
While specifics of his direct philanthropic activities aren't readily available, Rubiralta's family is involved with philanthropy. His mother presides over the foundation Nous Cims, which is focused on health and education projects, particularly in Senegal.
Assumed the role of Chairman at Werfen.
Relinquished the chairmanship of Werfen, remaining on the board.
